




FIG. 1A




FIG. 1B




FIG. 1C

FIG. 1D




FIG. 2B

FIG. 2A




FIG. 2D

FIG. 2C




FIG. 2F

FIG. 2E




FIG. 2H

FIG. 2G




FIG. 3A




FIG. 2I





FIG. 3C





FIG. 3B

10/55

Carboplatin
SNU5

20
15
10
5
0
-5
-10
-15
-20
-20
-15
-10
-5
0
5
10
15
20




FIG. 3E

Carboplatin
NUGC4

10
5
0
-5
-10
-10
-5
0
5
10




FIG. 3D




FIG. 4B




FIG. 4A




FIG. 4D




FIG. 4C




FIG. 4F




FIG. 4E




FIG. 4H




FIG. 4G




FIG. 5A




FIG. 5B




FIG. 5C




FIG. 5D




FIG. 5E




FIG. 5F




FIG. 5G




FIG. 5H




FIG. 5I




FIG. 5J




FIG. 6A








FIG. 6B



Average synergy: 47.931 (Bliss)

Average synergy: 51.923 (Bliss)




FIG. 9B




FIG. 9A




FIG. 11A




FIG. 11B




FIG. 10A




FIG. 10B




FIG. 12A




FIG. 12B




FIG. 12C




FIG. 12D

23/55




FIG. 13A




FIG. 13B




FIG. 13C




FIG. 13D




FIG. 14A




FIG. 14B




FIG. 14C




FIG. 14D

27/55




FIG. 15A




FIG. 15B




FIG. 15C




FIG. 15D




FIG. 16A




FIG. 16B




FIG. 16C




FIG. 16D




FIG. 17A




FIG. 17B




FIG. 17C




FIG. 17D




FIG. 18A




FIG. 18B




FIG. 18C




FIG. 18D

34/55

A2058




FIG. 19A




FIG. 19B

SUBSTITUTE SHEET (RULE 26)




FIG. 19C




FIG. 19D




FIG. 19E




FIG. 19F




FIG. 19G




FIG. 19H




FIG. 19I




FIG. 19J




FIG. 19K




FIG. 19L




FIG. 19M




FIG. 19N

41/55

KYSY410




FIG. 190




FIG. 19P

SUBSTITUTE SHEET (RULE 26)




FIG. 19Q




FIG. 19R




FIG. 19S




FIG. 19T




FIG. 19U




FIG. 19V




FIG. 19W




FIG. 19X

SNU-1




FIG. 19Y




FIG. 19Z

SUBSTITUTE SHEET (RULE 26)




FIG. 19AA




FIG. 19AB




FIG. 19AC




FIG. 19AD




FIG. 19AE




FIG. 19AF

50/55

MDA-MB-231 Triple Negative Breast Cancer Model




FIG. 20A

MDA-MB-231 Triple Negative Breast Cancer Model




FIG. 20B




FIG. 20C




FIG. 21A




FIG. 21C




FIG. 21B




FIG. 21D


52/55
Detroit 562

FIG. 22A




FIG. 22B




FIG. 22C




FIG. 22D




FIG. 23A




FIG. 23B




FIG. 23C




FIG. 23D




FIG. 24A




FIG. 24B